Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Combined With Nab-paclitaxel and SOX as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
NCT06576921Phase 2Active, not recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of serplulimab in gastric cancer (GC) and adenocarcinoma of the esophagogastric junction (AEG) (2 arms), sponsored by Xijing Hospital. Primary endpoint: Pathological complete response rate. Started Nov 2024; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
gastric cancer (GC)adenocarcinoma of the esophagogastric junction (AEG)
Beyond the preview
Go deeper on NCT06576921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06576921.